The Food and Drug Administration (FDA) has approved Novo Nordisk’s oral version of the Wegovy weight loss pill, the first such pill approved for use. Novo Nordisk said in a Tuesday release that the ...

For some, Dec. 23 may be Christmas Eve Eve. But it's also another holiday: A Festivus for the rest of us! That's right, it's the annual date in which Seinfeld fans celebrate with an aluminum pole, ...

The Food and Drug Administration approved the first-ever weight-loss pill on Monday, a move that is set to greatly expand the industry. Novo Nordisk’s GLP-1 weight-loss pill is a tablet formulation of ...

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The ...

The weight-loss drug market just got more crowded — and a lot less painful. The FDA on Monday approved a daily pill version of Novo Nordisk’s Wegovy, making it the first oral GLP-1 obesity treatment ...

The House on Thursday passed a bill that aims to speed up infrastructure and energy projects — with a new anti-wind amendment in order to get GOP hard-liners on board. The vote was 221-196. The SPEED ...

The agency greenlit an oral version of the obesity drug Wegovy. By Dani Blum The Food and Drug Administration on Monday approved a pill version of the weight-loss injectable drug Wegovy, offering ...

Credit: Tria Maret Aryuni/Shutterstock.com. Vandemoortele’s acquisition of bakery peer Délifrance has been approved by the European Commission conditional on the sale of two factories in France. To ...

The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Wegovy pill, as it’s called, is first oral version of a GLP-1 drug that ...

Some tout a daily semaglutide pill as a game-changer for weight-loss treatment. The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo ...

Please provide your email address to receive an email when new articles are posted on . Nerandomilast is the first oral preferential phosphodiesterase 4B inhibitor approved for progressive pulmonary ...